Neurologist Dr. Leah Croll talks about the new research suggesting they might help in treating people with alcohol use ...

The phase 2 ELAD study of Novo Nordisk's once-daily injectable GLP-1 agonist liraglutide in people with early-stage Alzheimer's has shown that the drug was able to reduce shrinking in the areas of ...

First-generation GLP-1 weight-loss drugs can help reduce the risk of obesity-related cancers, new research shows. Liraglutide ...

While natural approaches to raising GLP-1 are not as potent as medications, they provide a drug-free approach to weight loss ...

However, it is important to note that the study's cross-sectional design means these findings are correlational, not causal; the data do not show that these factors cause interest in GLP-1 use.

Eli Lilly announced Thursday the successful completion of a phase 3 trial of Orforglipron – the first small-molecule GLP-1 that is administered ... highest dose of the drug scored an A1C less ...

The diabetes and weight loss drugs are “not cost-effective at their current prices, and are largely unavailable to people with lower incomes,” the report said.

People booze a lot less when taking GLP-1 drugs like Ozempic, a new study out of Ireland ... statistics show. Monkey Business – stock.adobe.com Harmful alcohol use accounts for about 2.6 million ...

Scientists have been studying other possible health benefits of GLP-1s. Popular obesity and diabetes drugs called GLP-1 ... use disorder," Dr. Maurice O'Farrell, lead author of the study and ...

Ozempic and similar drugs aren’t just for weight loss, more and more research is finding. New data is the latest to show that GLP-1 medications ... for alcohol use disorder, the study ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds over 72 weeks, ...